SC
ARQT icon

Steven Cohen’s Arcutis Biotherapeutics ARQT Stock Holding History

Steven Cohen’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.5M Sell
362,449
-228,428
-39% -$5.32M 0.01% 1318
2026
Q1 		$13.9M Buy
590,877
+165,725
+39% +$4.23M 0.02% 1023
2025
Q4 		$12.3M Buy
+425,152
New +$10.9M 0.01% 1228
2025
Q3 		– Sell
-1,485,425
Closed -$20.8M – 2302
2025
Q2 		$20.8M Buy
1,485,425
+654,947
+79% +$9.18M 0.04% 479
2025
Q1 		$13M Sell
830,478
-923,044
-53% -$13M 0.03% 587
2024
Q4 		$24.4M Buy
1,753,522
+1,509,136
+618% +$16.5M 0.05% 394
2024
Q3 		$2.27M Buy
+244,386
New +$2.41M 0.01% 1152
2024
Q1 		– Sell
-320,300
Closed -$1.03M – 2161
2023
Q4 		$1.03M Buy
+320,300
New +$871K ﹤0.01% 1389
2023
Q1 		– Sell
-1,103,576
Closed -$16.3M – 2223
2022
Q4 		$16.3M Sell
1,103,576
-2,681,701
-71% -$46.9M 0.06% 392
2022
Q3 		$72.3M Buy
3,785,277
+1,797,846
+90% +$40.7M 0.29% 84
2022
Q2 		$42.4M Buy
1,987,431
+289,582
+17% +$5.94M 0.18% 151
2022
Q1 		$32.7M Sell
1,697,849
-946,328
-36% -$16M 0.13% 209
2021
Q4 		$54.8M Buy
2,644,177
+652,070
+33% +$13M 0.22% 118
2021
Q3 		$47.6M Buy
1,992,107
+1,095,707
+122% +$25M 0.21% 119
2021
Q2 		$24.5M Buy
896,400
+457,100
+104% +$12.9M 0.11% 240
2021
Q1 		$12.7M Sell
439,300
-435,900
-50% -$13.6M 0.06% 371
2020
Q4 		$24.6M Buy
875,200
+831,944
+1,923% +$20.4M 0.12% 230
2020
Q3 		$1.27M Buy
+43,256
New +$1.16M 0.01% 754

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Steven Cohen's ARQT Position: Q2 2026 in Review

Steven Cohen reduced its Arcutis Biotherapeutics (ARQT) stake by 39% in Q2 2026, selling an estimated $5.32M and leaving 362,449 shares worth $9.5M. The position accounts for 0.01% of the portfolio, ranked #1318.

Steven Cohen first reported a position in ARQT in Q3 2020 and has held it in 18 quarters since. The position peaked at $72.3M in Q3 2022. 271 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Steven Cohen held 362,449 shares of Arcutis Biotherapeutics worth $9.5M as of Q2 2026.
  • Steven Cohen sold 228,428 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.32M.
  • Arcutis Biotherapeutics made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1318 holding.
  • Steven Cohen first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 18 quarters since.
  • Steven Cohen's Arcutis Biotherapeutics position peaked at $72.3M in Q3 2022.
  • 271 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.